Breaking News

Sartorius Stedim Biotech Expands PAT Software Portfolio

December 18, 2012

To market Umetrics chemometrics software

Sartorius Stedim Biotech (SSB) has entered into a global sales partnership with Umetrics AB, a provider of chemometrics software for modeling and optimizing development and manufacturing processes. SSB will assume global marketing and distribution of Umetrics portfolio for the pharma and biopharma industries. Additionally, SSB will integrate Umetrics software programs as private label products into its own bioprocess portfolio and market the stand-alone solutions under both brands.
 
Stefan Schlack, senior vice president of marketing at SSB, said, “These software solutions will help our customers to better understand their cell culture processes and to identify potential for optimization and robust process control — an ideal addition to our bioprocess portfolio.”
 
“With SSB, we can gain access to substantially more customers thanks to its international reach and solid market standing in the biopharma sector. SSB’s integrated solutions for the complete biopharmaceutical process clearly create added value for our customers. I anticipate that this will considerably boost the biopharmaceutical industry’s interest in and usage of our products,” said Lars Lindstorm, general manager of Umetrics.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision